ImmunoGen, Inc.  

(Public, NASDAQ:IMGN)   Watch this stock  
Find more results for IMGN
17.05
-0.97 (-5.38%)
Real-time:   11:28AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.70 - 17.54
52 week 5.34 - 19.43
Open 17.18
Vol / Avg. 592,816.00/1.30M
Mkt cap 1.47B
P/E     -
Div/yield     -
EPS -0.66
Shares 86.19M
Beta 1.57
Inst. own 87%
Oct 22, 2015
Q1 2016 ImmunoGen Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Aug 12, 2015
ImmunoGen Inc at Canaccord Genuity Growth Conference - 1:00PM EDT - Add to calendar
Jul 31, 2015
Q4 2015 ImmunoGen Inc Earnings Release
Jul 31, 2015
Q4 2015 ImmunoGen Inc Earnings Call - Webcast
Jun 3, 2015
ImmunoGen Inc at Jefferies Global Healthcare Conference
May 6, 2015
ImmunoGen Inc at Credit Suisse Antibody Day
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -189.18% -119.15%
Operating margin -185.87% -119.43%
EBITD margin - -111.75%
Return on average assets -66.10% -37.67%
Return on average equity -126.45% -72.25%
Employees 307 -
CDP Score - -

Address

830 WINTER ST
WALTHAM, MA 02451
United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoGen, Inc. is a biotechnology company. The Company develops targeted anticancer therapeutics. The Company has three wholly-owned product candidates in clinical testing, with seven additional compounds in the clinic through its partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. The Company’s clinical-stage product candidates, include IMGN289, IMGN853 and IMGN529. IMGN289 compound is a treatment for many cases of head and neck cancers. IMGN853 compound is a potential treatment for epithelial ovarian cancer, endometrial cancer and other cancers. IMGN529 compound is used for the treatment of NHL (non-Hodgkin lymphoma). The Company’s IMGN529 ADC is a new treatment for cancers that express CD37, such as NHL and chronic lymphocytic leukemia.

Officers and directors

Stephen C. McCluski Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Daniel M. Junius President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Ellie Harrison Chief Human Resource Officer, Vice President
Age: 59
Bio & Compensation  - Reuters
Richard J Gregory Ph.D. Executive Vice President - Research, Chief Scientific Officer
Bio & Compensation  - Reuters
John M. Lambert Ph.D. Executive Vice President - Distinguished Research Fellow
Age: 63
Bio & Compensation  - Reuters
Sandra E. Poole Senior Vice President - Technical Operations.
Age: 51
Bio & Compensation  - Reuters
Craig Barrows Vice President, General Counsel, Secretary
Age: 59
Bio & Compensation  - Reuters
Anna Berkenblit M.D. Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
Peter J. Williams Vice President - Business Development
Age: 60
Bio & Compensation  - Reuters
Mark A. Goldberg M.D. Independent Director
Age: 54
Bio & Compensation  - Reuters